The Latest Breaking News from Cancer

SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last 24 hours, at $63.24 per share.

The Wanted have re-released a fan favourite track Gold Forever with all proceeds over the next 12 months going towards a brain tumour charity in memory of Tom Parker who sadly passed away after battling stage 4 glioblastoma - an aggressive form of brain cancer.

Labour MP Rosie Cooper campaigned for her 'first language' to be recognised in law, and will today get her wish after the campaign was backed by the government

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) will sell 953,834 common shares at $26.21 per share to Pfizer Inc (NYSE:PFE) for $25 million.  The offering is expected to close by April 29.  Zentalis will use the proceeds to fund ongoing and planned clinical trials, including studies of ZN-c3 and ZN-d5, and for working capital and general corporate…

Youngs' wife, Tiffany, was diagnosed with Hodgkin’s lymphoma, a type of blood cancer, shortly after giving birth to her daughter Maisie in 2014

Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…

The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months…

Here's a roundup of top developments in the biotech space over the last 24 hours.

Bill Brown is refusing to give in to old age and will be hitting the road for the Gateshead Half Marathon on May 1 in aid of Pancreatic Cancer UK